dc.creator | del Portillo, Hernando | |
dc.creator | Badimón, Juan J. | |
dc.creator | Cabrales Arevalo, Jaime Ramon | |
dc.creator | Echeverri Arcila, Darío | |
dc.date.accessioned | 2019-01-22T16:48:10Z | |
dc.date.available | 2019-01-22T16:48:10Z | |
dc.date.created | 2019-01-22T16:48:10Z | |
dc.date.issued | 2016 | |
dc.identifier | ISSN 0120-5633 | |
dc.identifier | http://repository.urosario.edu.co/handle/10336/18904 | |
dc.language | spa | |
dc.relation | Revista Colombiana de Cardiologia, ISSN: 0120-5633, Vol. 23/No. 6 (2016) pp. 461-463 | |
dc.relation | https://www.clinicalkey.es/service/content/pdf/watermarked/1-s2.0-S0120563316301875.pdf?locale=es_ES | |
dc.relation | 463 | |
dc.relation | No. 6 | |
dc.relation | 461 | |
dc.relation | Revista Colombiana de Cardiologia | |
dc.relation | Vol. 23 | |
dc.rights | | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.rights | Abierto (Texto Completo) | |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.source | instname:Universidad del Rosario | |
dc.source | reponame:Repositorio Institucional EdocUR | |
dc.subject | Acetylsalicylic Acid | |
dc.subject | Anticoagulant Agent | |
dc.subject | Antivitamin K | |
dc.subject | Apixaban | |
dc.subject | Clopidogrel | |
dc.subject | Dabigatran | |
dc.subject | Fibrinolytic Agent | |
dc.subject | Glycoprotein Iib Inhibitor | |
dc.subject | Glycoprotein Iiia Inhibitor | |
dc.subject | P2Y12 Receptor Inhibitor | |
dc.subject | Protein Inhibitor | |
dc.subject | Rivaroxaban | |
dc.subject | Ticagrelor | |
dc.subject | Unclassified Drug | |
dc.subject | Warfarin | |
dc.subject | Anticoagulation | |
dc.subject | Atrial Fibrillation | |
dc.subject | Bleeding | |
dc.subject | Cardiovascular Mortality | |
dc.subject | Cerebrovascular Accident | |
dc.subject | Clinical Research | |
dc.subject | Colombia | |
dc.subject | Combination Chemotherapy | |
dc.subject | Coronary Artery Disease | |
dc.subject | Dose Response | |
dc.subject | Drug Administration Route | |
dc.subject | Drug Efficacy | |
dc.subject | Drug Eluting Stent | |
dc.subject | Drug Indication | |
dc.subject | Drug Research | |
dc.subject | Drug Safety | |
dc.subject | Echocardiography | |
dc.subject | Follow Up | |
dc.subject | Heart Death | |
dc.subject | Heart Ejection Fraction | |
dc.subject | Heart Infarction | |
dc.subject | Heart Muscle Ischemia | |
dc.subject | Heart Ventricle Thrombosis | |
dc.subject | Human | |
dc.subject | International Normalized Ratio | |
dc.subject | Intracoronary Drug Administration | |
dc.subject | Monotherapy | |
dc.subject | Percutaneous Coronary Intervention | |
dc.subject | Phase 2 Clinical Trial (Topic) | |
dc.subject | Prophylaxis | |
dc.subject | Risk Assessment | |
dc.subject | Secondary Prevention | |
dc.subject | Thrombectomy | |
dc.subject | Treatment Withdrawal | |
dc.title | Papel de los nuevos anticoagulantes orales en el tratamiento de la enfermedad coronaria | |
dc.type | contributionToPeriodical | |